Wolverine Trading
LCTX icon

Wolverine Trading’s Lineage Cell Therapeutics LCTX Stock Holding History

Wolverine Trading’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,482
Closed -$34.6K – 6633
2021
Q2 		$40K Sell
13,482
-3,872
-22% -$10K ﹤0.01% 5637
2021
Q1 		$39K Buy
+17,354
New +$41.7K ﹤0.01% 5697
2019
Q3 		– Sell
-13,323
Closed -$15K – 4721
2019
Q2 		$15K Sell
13,323
-14,848
-53% -$17.1K ﹤0.01% 4299
2019
Q1 		$37K Buy
+28,171
New +$35K ﹤0.01% 4350
2018
Q4 		– Sell
-14,497
Closed -$30K – 4947
2018
Q3 		$30K Buy
14,497
+546
+4% +$1.15K ﹤0.01% 4776
2018
Q2 		$33K Hold
13,951
– – ﹤0.01% 4975
2018
Q1 		$33K Sell
13,951
-18,487
-57% -$43.4K ﹤0.01% 4975
2017
Q4 		$61K Buy
+32,438
New +$70.8K ﹤0.01% 4570
2017
Q3 		– Sell
-16,017
Closed -$39.7K – 4748
2017
Q2 		$44K Sell
16,017
-4,566
-22% -$12.8K ﹤0.01% 4078
2017
Q1 		$60K Buy
+20,583
New +$58.5K ﹤0.01% 3962
2016
Q3 		– Sell
-26,559
Closed -$58K – 4857
2016
Q2 		$58K Buy
+26,559
New +$65.1K ﹤0.01% 3794

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wolverine Trading's LCTX Position: Q3 2021 in Review

Wolverine Trading sold out of Lineage Cell Therapeutics (LCTX) in Q3 2021, closing a stake of 13,482 shares — an estimated $34.6K sold.

Wolverine Trading first reported a position in LCTX in Q2 2016 and held it in 11 quarters. The position peaked at $61K in Q4 2017. 115 funds tracked by Wall St. Rank hold LCTX as of Q3 2021.

  • Wolverine Trading reported no remaining Lineage Cell Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Wolverine Trading sold 13,482 Lineage Cell Therapeutics shares in Q3 2021, an estimated $34.6K.
  • Wolverine Trading first reported a position in Lineage Cell Therapeutics in Q2 2016 and held it in 11 quarters.
  • Wolverine Trading's Lineage Cell Therapeutics position peaked at $61K in Q4 2017.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2021.

Based on Wolverine Trading's 13F filing for Q3 2021, filed 12 Nov 2021.